Drug company Abbvie wins patent dispute with charity
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Drug company Abbvie wins patent dispute with charity

Research charity The Kennedy Institute of Rheumatology Trust has lost a patent dispute to pharmaceutical company AbbVie over the rights to Humira, the world’s top-selling drug

The District Court for the Southern District of New York found last month that several claims in the patent, owned by the Kennedy Institute, were invalid.

Before the ruling, the Kennedy Trust had collected more than $100 million in royalties from AbbVie on the patent and hundreds of millions more in royalties from competitors.

The case, AbbVie and AbbVie Biotechnology v The Kennedy Institute of Rheumatology Trust, concerned the Kennedy Institute’s claims relating to US patent 7,846,442, titled “Treatment of Autoimmune and Inflammatory Disorders”. It was argued in September 2012 and the ruling was delivered on June 20 this year.

Judge Paul Crotty found claims 1 through 7, 13, 14, and 17 through 20 invalid for obviousness, and denied the Kennedy Institute’s counterclaim for a declaratory judgment that the claims in question are not invalid.

more from across site and ros bottom lb

More from across our site

Partners and other senior leaders must step up if they want diverse talent at their firms to thrive
European and US counsel reveal why they are (or aren't) concerned about patent quality and explain how external counsel can help
Firms such as Bird & Bird and Taylor Wessing have reported rising profits and highlighted the role of high-profile IP disputes and hires
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Lawyers in the corporate and IP practices discuss where the firm can steal a march on competitors, its growth plans in London, and why deal lawyers are ‘concertmasters’
Kathleen Gaynor, DEI specialist at Phillips Ormonde Fitzpatrick, says deliberate actions can help law firms reach diversity goals
Scott McKeown, who moved to Wolf Greenfield one year ago, says the change has helped him tap into life sciences work and advise more patent owners
The winners of our Asia-Pacific Awards 2024 will be revealed during a ceremony in Malaysia on September 26
Zach Piccolomini of Wolf Greenfield explains how to maximise your IP portfolio’s value while keeping an eye on competitors
Witnesses at a Congressional hearing debated whether reforming the ITC is necessary and considered what any changes should look like
Gift this article